Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

Next Previous
Trial Profile

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donanemab (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Dementia
  • Focus Therapeutic Use
  • Acronyms TRAILBLAZER-REAL US
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 28 Oct 2024 Status changed from not yet recruiting to recruiting.
  • 27 Aug 2024 New trial record
  • 01 Aug 2024 Trial design presented at the Alzheimer's Association International Conference 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top